Company: DMAC
Filing Date: 2025-08-06
Form Type: 8-K
Source: 0001437749-25-024956
Chunk: 2

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-06
Form: 8-K
Item: Item 8.01
Chunk 2
---
Item 8.01 Other Events.

On July 31, 2025, the Company appointed Julie Krop, M. D., to serve as Chief Medical Officer of the Company, effective as of August 11, 2025. Over the course of her career in biotech and pharmaceuticals, Dr. Krop more than 20 years of experience as a strategic physician executive with leadership experience spanning multiple therapeutic and orphan indications in both pre-commercial and commercial organizations. She joins DiaMedica from PureTech Health, where she was CMO and Head of Development, leading multiple rare disease programs from preclinical development through Phase 2 trials. Prior, she served as CMO at Freeline Therapeutics, where she helped drive a successful IPO and oversaw three clinical stage gene therapy programs. Before that, Dr. Krop was CMO and executive vice president at AMAG Pharmaceuticals, where she was involved in the approval of three drugs and worked on the development of an orphan drug candidate for the treatment of severe preeclampsia. Previously, Dr. Krop has held senior development roles at Vertex Pharmaceuticals, Stryker Regenerative Medicine, Peptimmune, Millennium Pharmaceuticals, and Pfizer. Dr. Krop received her MD from Brown University School of Medicine and completed her residency at Georgetown University Hospital. She also completed fellowships in epidemiology, clinical trial design and endocrinology at Johns Hopkins School of Medicine. Dr. Krop is board-certified in Endocrinology.

  Item 9.01.      Financial Statements and Exhibits.  

  (d)      Exhibits.  

The following exhibit is furnished herewith:

  Exhibit                                                                                                                   
   Number      Description                                                                                                  
     10.1      Separation Agreement between DiaMedica Therapeutics Inc. and Lorianne Masuoka, M. D., dated August 5, 2025.  
     99.1      Press release dated August 6, 2025, announcing the appointment of Julie Krop, M. D.                          
      104      Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).        

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  DIAMEDICA THERAPEUTICS INC.                                             
  By:                              /s/ Scott Kellen                       
                                   Scott Kellen                           
                                   Chief Financial Officer